T. Rowe Price Associates
TPTX

T. Rowe Price Associates’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

T. Rowe Price Associates’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-953,914
Closed -$71.8M – 3089
2022
Q2 		$71.8M Sell
953,914
-3,008,738
-76% -$134M 0.01% 755
2022
Q1 		$106M Buy
3,962,652
+151,084
+4% +$5.08M 0.01% 710
2021
Q4 		$182M Buy
3,811,568
+525,687
+16% +$23.5M 0.02% 584
2021
Q3 		$218M Buy
3,285,881
+391,786
+14% +$27.9M 0.02% 523
2021
Q2 		$226M Buy
2,894,095
+373,052
+15% +$27.6M 0.02% 528
2021
Q1 		$238M Sell
2,521,043
-24,742
-1% -$2.94M 0.02% 504
2020
Q4 		$310M Buy
2,545,785
+594,067
+30% +$65.1M 0.03% 416
2020
Q3 		$171M Buy
1,951,718
+44,489
+2% +$3.1M 0.02% 522
2020
Q2 		$123M Buy
1,907,229
+564,690
+42% +$32.6M 0.02% 577
2020
Q1 		$60M Sell
1,342,539
-152,887
-10% -$8.12M 0.01% 723
2019
Q4 		$93.2M Buy
1,495,426
+280,569
+23% +$13.4M 0.01% 690
2019
Q3 		$45.7M Buy
1,214,857
+324,807
+36% +$14.1M 0.01% 904
2019
Q2 		$36.2M Buy
+890,050
New +$31.7M 0.01% 989

T. Rowe Price Associates's TPTX Position: Q3 2022 in Review

T. Rowe Price Associates sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 953,914 shares — an estimated $71.8M sold.

T. Rowe Price Associates first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $310M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • T. Rowe Price Associates reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 953,914 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $71.8M.
  • T. Rowe Price Associates first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • T. Rowe Price Associates's Turning Point Therapeutics, Inc. Common Stock position peaked at $310M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.